TY - JOUR
T1 - Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia
AU - Skulas-Ray, Ann C.
AU - Alaupovic, Petar
AU - Kris-Etherton, Penny M.
AU - West, Sheila G.
N1 - Funding Information:
GlaxoSmithKline provided financial support of this study. diaDexus performed the Lp-PLA 2 testing for the study. Kenneth Colley, formerly of diaDexus, provided input on interpretation of Lp-PLA 2 results. A.C.S. received fellowship support from the National Fisheries Institute. The authors thank the nursing and clinician staff of the Clinical Research Center, part of The Pennsylvania State University Clinical and Translational Science Institute, which is supported by the National Center for Advancing Translational Sciences , National Institutes of Health , through Grant UL1 TR000127 . The authors also thank Dr J. Butler for her technical assistance and Mrs N. Simpson for her editorial assistance.
Publisher Copyright:
© 2015 National Lipid Association.
PY - 2015/5/1
Y1 - 2015/5/1
N2 - Background Apolipoprotein (apo) distribution and lipoprotein (Lp)-associated markers of inflammation, such as lipoprotein-associated phospholipase A2 (Lp-PLA2), influence the atherogenicity of circulating lipids and lipoproteins. Little evidence exists regarding the dose-response effects of the marine omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on apos, apo-defined Lps, and Lp-PLA2. Objective The purpose of this study was to compare the effects of 0, 0.85, and 3.4 g/d of EPA + DHA on Lp-PLA2 mass and activity in individuals with moderate hypertriglyceridemia. We also measured effects on concentrations of apoAI, apoAII, apoB, apoC, apoD, and apoE-defined Lp subclasses. Methods The study was a randomized, doubleblind, crossover design with 8-week treatment periods and 6-week washout periods. During the 3 treatment periods, subjects (n = 25) received 0 g/d EPA + DHA, 0.85 g/d EPA + DHA (low dose), and 3.4 g/d EPA + DHA (high dose) in random order. Results apoB and apoC-III were significantly decreased by the high dose relative to placebo and low dose (P <.01), as was very low-density lipoprotein cholesterol (P <.005). The low dose had no effect on Lp outcomes compared with placebo. The high- and low-dose effects differed significantly for heparin-precipitated apoC-III, LpB, LpA-I, and apoB/apoA-I ratio (P <.05). There was a trend for a decreased Lp-PLA2 mass with the high dose (P =.1). Conclusion The effects of 3.4 g/d EPA + DHA on apoB and apoC-III may reduce atherosclerotic plaque progression in individuals with elevated triglycerides.
AB - Background Apolipoprotein (apo) distribution and lipoprotein (Lp)-associated markers of inflammation, such as lipoprotein-associated phospholipase A2 (Lp-PLA2), influence the atherogenicity of circulating lipids and lipoproteins. Little evidence exists regarding the dose-response effects of the marine omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on apos, apo-defined Lps, and Lp-PLA2. Objective The purpose of this study was to compare the effects of 0, 0.85, and 3.4 g/d of EPA + DHA on Lp-PLA2 mass and activity in individuals with moderate hypertriglyceridemia. We also measured effects on concentrations of apoAI, apoAII, apoB, apoC, apoD, and apoE-defined Lp subclasses. Methods The study was a randomized, doubleblind, crossover design with 8-week treatment periods and 6-week washout periods. During the 3 treatment periods, subjects (n = 25) received 0 g/d EPA + DHA, 0.85 g/d EPA + DHA (low dose), and 3.4 g/d EPA + DHA (high dose) in random order. Results apoB and apoC-III were significantly decreased by the high dose relative to placebo and low dose (P <.01), as was very low-density lipoprotein cholesterol (P <.005). The low dose had no effect on Lp outcomes compared with placebo. The high- and low-dose effects differed significantly for heparin-precipitated apoC-III, LpB, LpA-I, and apoB/apoA-I ratio (P <.05). There was a trend for a decreased Lp-PLA2 mass with the high dose (P =.1). Conclusion The effects of 3.4 g/d EPA + DHA on apoB and apoC-III may reduce atherosclerotic plaque progression in individuals with elevated triglycerides.
UR - http://www.scopus.com/inward/record.url?scp=84931562605&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84931562605&partnerID=8YFLogxK
U2 - 10.1016/j.jacl.2014.12.001
DO - 10.1016/j.jacl.2014.12.001
M3 - Article
C2 - 26073395
AN - SCOPUS:84931562605
SN - 1933-2874
VL - 9
SP - 360
EP - 367
JO - Journal of Clinical Lipidology
JF - Journal of Clinical Lipidology
IS - 3
ER -
